Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

J Duell; P Abrisqueta; M Andre; M Augustin; G Gaidano; EG Barca; W Jurczak; N Kalakonda; AM Liberati; KJ Maddocks; T Menne; Z Nagy; O Tournilhac; A Bakuli; A Amin; K Gurbanov; G Salles

doi:10.1016/S2152-2650

Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

J Duell, P Abrisqueta, M Andre, M Augustin, G Gaidano, EG Barca, W Jurczak, N Kalakonda, AM Liberati, KJ Maddocks, T Menne, Z Nagy, O Tournilhac, A Bakuli, A Amin, K Gurbanov, G Salles

Universitätsklinik für Innere Medizin 5 - Onkologie und Hämatologie

Publikation: Beitrag in Fachzeitschrift › publizierter Abstrakt (Zeitschrift) › Begutachtung

Originalsprache	Englisch
Seiten (von - bis)	S433-S434
Seitenumfang	2
Fachzeitschrift	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Jahrgang	23
DOIs	https://doi.org/10.1016/S2152-2650
Publikationsstatus	Veröffentlicht - Sept. 2023

Zugriff auf Dokument

10.1016/S2152-2650

Dieses zitieren

Duell, J., Abrisqueta, P., Andre, M., Augustin, M., Gaidano, G., Barca, EG., Jurczak, W., Kalakonda, N., Liberati, AM., Maddocks, KJ., Menne, T., Nagy, Z., Tournilhac, O., Bakuli, A., Amin, A., Gurbanov, K., & Salles, G. (2023). Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 23, S433-S434. https://doi.org/10.1016/S2152-2650

@article{7034da269a4c4b639f7c4b8b0e62632b,

title = "Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study",

keywords = "tafasitamab, lenalidomide, diffuse large B-cell lymphoma (DLBCL), immunotherapy, L-MIND",

author = "J Duell and P Abrisqueta and M Andre and M Augustin and G Gaidano and EG Barca and W Jurczak and N Kalakonda and AM Liberati and KJ Maddocks and T Menne and Z Nagy and O Tournilhac and A Bakuli and A Amin and K Gurbanov and G Salles",

year = "2023",

month = sep,

doi = "10.1016/S2152-2650",

language = "English",

volume = "23",

pages = "S433--S434",

journal = "CLINICAL LYMPHOMA MYELOMA & LEUKEMIA",

issn = "2152-2650",

}

Duell, J, Abrisqueta, P, Andre, M, Augustin, M, Gaidano, G, Barca, EG, Jurczak, W, Kalakonda, N, Liberati, AM, Maddocks, KJ, Menne, T, Nagy, Z, Tournilhac, O, Bakuli, A, Amin, A, Gurbanov, K & Salles, G 2023, 'Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study', CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Jg. 23, S. S433-S434. https://doi.org/10.1016/S2152-2650

Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study. / Duell, J; Abrisqueta, P; Andre, M et al.
in: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Jahrgang 23, 09.2023, S. S433-S434.

Publikation: Beitrag in Fachzeitschrift › publizierter Abstrakt (Zeitschrift) › Begutachtung

TY - JOUR

T1 - Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

AU - Duell, J

AU - Abrisqueta, P

AU - Andre, M

AU - Augustin, M

AU - Gaidano, G

AU - Barca, EG

AU - Jurczak, W

AU - Kalakonda, N

AU - Liberati, AM

AU - Maddocks, KJ

AU - Menne, T

AU - Nagy, Z

AU - Tournilhac, O

AU - Bakuli, A

AU - Amin, A

AU - Gurbanov, K

AU - Salles, G

PY - 2023/9

Y1 - 2023/9

KW - tafasitamab

KW - lenalidomide

KW - diffuse large B-cell lymphoma (DLBCL)

KW - immunotherapy

KW - L-MIND

U2 - 10.1016/S2152-2650

DO - 10.1016/S2152-2650

M3 - published Abstract (Journal)

SN - 2152-2650

VL - 23

SP - S433-S434

JO - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

JF - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

ER -